• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Lyrica (pregabalin) is approved for fibromyalgia

Lyrica (pregabalin) is approved for fibromyalgia

August 1, 2007
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jesse H. Wright, MD

Fibromyalgia is a condition character- ized by at least 3 months of widespread pain (both above and below the waist and on both sides of the body) and by the presence of at least 11 tender points (these are the official American College of Rheumatology criteria). There are no diag- nostic tests for fibromyalgia, and it is a diagnosis of exclusion. Recently, the FDA announced approval for Lyrica (prega- balin, the “cousin” of Neurontin, or gabapentin) for the treatment of fibromyalgia, based on two double-blind placebo controlled trials involving 1800 patients. Effective doses ranged from 300 to 450 mg/day.

TCPR’s Take: We have not yet seen the data upon which the FDA’s approval was based, although a brief summary of some of this data is presented on the Pfizer website, in their updated Lyrica product insert (http://www.pfizer.com/ pfizer/download/uspi_lyrica.pdf). The key questions will be whether Lyrica does better than tricyclics or SNRIs, both of which are effective in fibromyalgia (though neither class has FDA approval). Lyrica has a fairly negative side effect profile, including high rates of sedation and dizziness, and has some abuse liability, being classified in the same DEA schedule as cough suppressants with codeine.

General Psychiatry
    www.thecarlatreport.com
    Issue Date: August 1, 2007
    SUBSCRIBE NOW
    Table Of Contents
    Screening Labs for New Patients: Are they Useful?
    Laboratory Monitoring When Prescribing Psychotropics
    Pharmacogenetic Testing in Psychiatry
    Do SSRIs cause osteoporosis?
    Lyrica (pregabalin) is approved for fibromyalgia
    Metaanalysis shows no difference between SSRIs and bupropion
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.